Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Cancer Research and Clinic ; (6): 42-44,51, 2014.
Article in Chinese | WPRIM | ID: wpr-553989

ABSTRACT

Objective To compare the efficacy and toxicity of SOX and FOLFOX4 regimen in the treatment of advanced gastric cancer.Methods Total of 32 patients with advanced gastric cancer proved pathologically were randomly divided into 2 groups:16 patients received SOX regimen [oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1,S-1 capsules 80 mg/(m-2·d) twice a day per oral from day 1 to day 14 every 3 weeks],the other 16 patients received FOLFOX4 regimen [oxaliplatin 85 mg/m2 as a 2-hour infusion on day 1 and a 2-hour infusion of LV 200/(m2· d) followed by a 5-Fu bolus 400/(m2· d) and 22-hour infusion 600/(m2· d) for 2 consecutive days every 2 weeks].Efficacy was evaluated at least 2 cycles.Results The response rates of SOX group and FOLFOX4 group were 56.25 % (9/16) and 43.57 % (7/16),the disease control rates were 81.25 % (13/16) and 75.00 % (12/16).The median progress free survival times were 7.2 months and 5.6 months,the median overall survival times were 9.4 months and 7.9 months.The main toxicity in the two groups was hematological toxicity,nausea/vomiting,and peripheral neuropathy.The main grade 3 hematologic toxicity was neutropenia,with no significant difference between them [12.50 % (2/16) vs 31.25 % (5/16),P =0.394].Conclusions Both SOX and FOLFOX4 regimens are effective for patients with advanced gastric cancer.Compared with FOLFOX4 regimen,SOX regimen is better tolerated for advanced gastric cancer with longer progress free survival and overall survival.

SELECTION OF CITATIONS
SEARCH DETAIL